All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
47 results for "Cancer" and "Gastrointestinal Cancers"
Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced / Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
This clinical trial tests an investigational drug, STP705, that has shown through laboratory experiments to silence TGF-1 and COX-2 gene expressions, enzyme proteins believed to speed cancer growth in some cancers, which may result in tumor shrinkage when administered.
Protocol No
SIRNAOMICS-SRN-705-005
Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Testing the addition of bevacizumab to AZD9291 (osimertinib) as a first-treatment for patients with EGFR-mutant lung cancer that has metastasized
Protocol No
ECOG-EA5182
Sub Category
Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis
Improving the Treatment of Immunotherapy-related Lung Inflammation in Patients where Corticosteroids are No Longer Effective
Protocol No
ECOG-EAQ172
Sub Category
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients, NCCAPS Study. How does COVID19 affect the outcomes of people undergoing cancer treatment? How does having cancer affect COVID-19?
Protocol No
NCI-COVID-NCCAPS
Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Protocol No
IIT-MCGONIGLE-ONA-NEUROPATHY
Sub Category
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated,NS-NSCLC
Protocol No
CALITHERA-CX-839-014-KEAPSAKE
Sub Category
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Testing the effects of MK-3475 (pembrolizumab) with or without the usual chemotherapy treatment for patients 70 years of age and older with advanced non-small cell lung cancer
Protocol No
ALLIANCE-A171901
Sub Category
Recognition of Circulating Tumor DNA in Sarcoma
Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma
Protocol No
IIT-BEDI-CTDNA
Sub Category
Phase 1/1b Study To Evaluate The Safety And Activity Of TTX-030 (Anti-CD39) In Combination With Budigalimab And/Or Chemotherapy In Subjects With Advanced Solid Tumors
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Protocol No
TRISHULA-TTX-030-002
A Phase Ib/II Study of the Microenvironment Modifier L-DOS47 Plus Doxorubicin for the Treatment of Patients with Previously Treated Advanced Pancreatic Cancer
The purpose of this study is to evaluate in patients with metastatic pancreatic cancer, the overall safety, tolerability, and preliminary anti-tumor activity of adding an investigational drug, L DOS47, to doxorubicin, a type of chemotherapy drug
Protocol No
HELIX-LDOS006
A Multicenter Phase II Trial Of Paclitaxel With And Without Nivolumab In Taxane Naïve, And Nivolumab And Cabozantinib In Taxane Pretreated Subjects With Angiosarcoma
Testing the Addition of Nivolumab to chemotherapy in Treatment of Soft Tissue Sarcoma
Protocol No
ALLIANCE-A091902
Sub Category
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-small Cell Lung Cancer
Durvalumab Following SBRT for the Treatment of Patients with Stage I/II NSCLC
Protocol No
AZ-D9103C00001-PACIFIC-4
Sub Category
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)
Durvalumab or Durvalumab and Tremelimumab for Patients with Stage I-III LLimited Disease SCLC
Protocol No
AZ-D933QC00001-ADRIATIC
Sub Category
Randomized, open label Phase 3 study of SAR408701 versus Docetaxel in previously treated metastatic non-squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors
Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic Non-Squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors (CARMEN-LC03)
Protocol No
SANOFI-EFC15858
Sub Category
Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Testing the Addition of an Antibody toStandard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients
With Unresectable Stage III Non-Small Cell Lung Cancer
With Unresectable Stage III Non-Small Cell Lung Cancer
Protocol No
ECOG-EA5181
Sub Category
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
Protocol No
ECOG-EA2182-DECREASE
Sub Category
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineer NY-ESO-1 Specified (c259) T Cells, Alone or in combination with other agents, in HLA-A@+ Participants with NY-ESO-1 and/or LAGE -1a Positive Solid Tumors
Study of Genetically Engineered T Cells in NY-ESO-1 +/or LAGE-1a + Solid Tumors
Protocol No
GSK-3377794-208467-SARCOMA
Sub Category
Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST chemo-IO
Testing the addition of a type of drug called immunotherapy to the usual chemotherapy treatment for non-small cell lung cancer
Protocol No
ALLIANCE-ALCHEMIST-A081801
Sub Category
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
The purpose of this research study is to compare any good and bad effects of giving
ipilimumab, nivolumab, and GM-CSF (Sargramostim) at the same time compared to just
ipilimumab and nivolumab together. We would also like to find out what effects, good
and bad, that this combination of drugs may have on your cancer. This study will involve
the addition of the FDA approved agent nivolumab to the standard FDA approved
ipilimumab immunotherapy in the hopes that it might further improve the good effects of
the immunotherapy component of the treatment sequence. The combination of
ipilimumab and nivolumab has been shown in recent studies to produce superior
antitumor effects but also more side effects than ipilimumab alone. This combination
has received FDA approval for patients with BRAF V600 wild-type unresectable or
metastatic melanoma. This combination is under review for FDA approval for patients
with BRAF V600 mutant melanoma and is therefore still considered to be experimental
for these patients. GM-CSF is a protein that your body normally produces to signal to
your body to make white blood cells. White blood cells are very important in the body s
defense system as they help identify and destroy foreign invaders, such as bacteria,
viruses, and cells that don t belong, such as cancer cells. Injections of GM-CSF
increase your body s production of white blood cells and also help enhance the function
of the white blood cells. This research study will allow the researchers to know whether
this different approach is better, the same, or worse than the usual approach. To be
better, the study drugs should improve how long you are able to live with your cancer
compared to the usual approach. There will be about 400 people taking part in this
research study, including approximately 15 at this site.
ipilimumab, nivolumab, and GM-CSF (Sargramostim) at the same time compared to just
ipilimumab and nivolumab together. We would also like to find out what effects, good
and bad, that this combination of drugs may have on your cancer. This study will involve
the addition of the FDA approved agent nivolumab to the standard FDA approved
ipilimumab immunotherapy in the hopes that it might further improve the good effects of
the immunotherapy component of the treatment sequence. The combination of
ipilimumab and nivolumab has been shown in recent studies to produce superior
antitumor effects but also more side effects than ipilimumab alone. This combination
has received FDA approval for patients with BRAF V600 wild-type unresectable or
metastatic melanoma. This combination is under review for FDA approval for patients
with BRAF V600 mutant melanoma and is therefore still considered to be experimental
for these patients. GM-CSF is a protein that your body normally produces to signal to
your body to make white blood cells. White blood cells are very important in the body s
defense system as they help identify and destroy foreign invaders, such as bacteria,
viruses, and cells that don t belong, such as cancer cells. Injections of GM-CSF
increase your body s production of white blood cells and also help enhance the function
of the white blood cells. This research study will allow the researchers to know whether
this different approach is better, the same, or worse than the usual approach. To be
better, the study drugs should improve how long you are able to live with your cancer
compared to the usual approach. There will be about 400 people taking part in this
research study, including approximately 15 at this site.
Protocol No
ECOG-EA6141
Sub Category
A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer
The purpose of this study is to test the anti-cancer activity of NUC-1031 when given in
combination with Cisplatin, and to compare it with the standard treatment of Gemcitabine in
combination with Cisplatin in people with biliary tract cancer.
combination with Cisplatin, and to compare it with the standard treatment of Gemcitabine in
combination with Cisplatin in people with biliary tract cancer.
Protocol No
NUCANA-NUTIDE-121
Sub Category
Randomized Double-Blind Phase III Trial Of Vitamin D3 Supplementation In Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer (SOLARIS). This study is being done to answer the following question: Can we lower the chance of your colorectal cancer growing or spreading by adding a new drug to the usual combination of drugs?
Protocol No
ALLIANCE-A021703-SOLARIS
Sub Category